Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Tobacco Use Disorder 1Lymphoproliferative Disorders 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 220Rituximab 189fludarabine phosphate 169fludarabine 102Peripheral Blood Stem Cell Transplantation 100Mycophenolic Acid 94Whole-Body Irradiation 81Tacrolimus 72Filgrastim 69Cyclosporine 67Lenalidomide 66ibrutinib 63Busulfan 61Melphalan 58Antilymphocyte Serum 57Radiotherapy 52venetoclax 48Etoposide 47obinutuzumab 42Bendamustine Hydrochloride 42Alemtuzumab 41Methotrexate 39ofatumumab 28sargramostim 27Granulocyte Colony-Stimulating Factor 26Cytarabine 26Cord Blood Stem Cell Transplantation 26acalabrutinib 25Stem Cell Transplantation 24Specimen Handling 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphocytic, Chronic, B-Cell × phenethyl isothiocyanate × Clear all
NCT00968461 2013-04-15

Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡